Cempra (CEMP) Receiving Somewhat Favorable Press Coverage, Analysis Shows
News headlines about Cempra (NASDAQ:CEMP) have trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cempra earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.8157167402639 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Brokerages Expect Cempra, Inc. (CEMP) Will Announce Earnings of -$0.17 Per Share (americanbankingnews.com)
- Cempra, Inc. (CEMP) Given Average Rating of “Hold” by Analysts (americanbankingnews.com)
- Cempra, Inc. (CEMP) Given Hold Rating at Jefferies Group LLC (americanbankingnews.com)
- CEMPRA (CEMP) Presents At Morgan Stanley 15th Annual Global Healthcare Conference – Slideshow (seekingalpha.com)
- Catalent, Inc. (CTLT) registers a price change of 1.09% while Cempra, Inc. (CEMP) – Stocks Gallery (stocksgallery.com)
Several brokerages recently issued reports on CEMP. Jefferies Group LLC reiterated a “hold” rating and issued a $3.00 price objective on shares of Cempra in a research report on Thursday, September 14th. Stifel Nicolaus reiterated a “hold” rating and issued a $4.00 price objective on shares of Cempra in a research report on Thursday, August 10th. Roth Capital lowered Cempra from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $8.00 to $4.00 in a research report on Thursday, August 10th. Zacks Investment Research upgraded Cempra from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a research report on Friday, August 11th. Finally, ValuEngine lowered Cempra from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Four investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $10.00.
Shares of Cempra (NASDAQ:CEMP) opened at 3.1676 on Tuesday. Cempra has a 1-year low of $2.55 and a 1-year high of $26.95. The company’s market cap is $166.32 million. The firm has a 50-day moving average price of $3.20 and a 200 day moving average price of $3.80.
Cempra (NASDAQ:CEMP) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.09. Cempra had a negative return on equity of 53.99% and a negative net margin of 560.40%. The firm had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $3.58 million. During the same quarter last year, the firm posted ($0.51) earnings per share. The company’s revenue for the quarter was down 74.9% compared to the same quarter last year. On average, equities analysts anticipate that Cempra will post ($1.01) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/cempra-cemp-receiving-somewhat-favorable-press-coverage-analysis-shows/1573128.html.
Cempra Company Profile
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.